Skip Navigation


NDT Advance Access originally published online on April 9, 2008
Nephrology Dialysis Transplantation 2008 23(6):1786-1789; doi:10.1093/ndt/gfn142
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/6/1786    most recent
gfn142v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Olgaard, K.
Right arrow Articles by Lewin, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olgaard, K.
Right arrow Articles by Lewin, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Use (or misuse) of vitamin D treatment in CKD and dialysis patients

A recent meta-analysis on vitamin D compounds in chronic kidney disease [1] and an editorial comment [2] accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership

Klaus Olgaard1 and Ewa Lewin2

1 Nephrological Department P, Rigshospitalet 2 Nephrological Department B, Herlev Hospital, University of Copenhagen, Denmark

Correspondence and offprint requests to: Klaus Olgaard, Department of Nephrology P2132, University of Copenhagen, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. Tel: +45-3545-2130; Fax: +45-3545-2672; E-mail: olgaard@rh.dk

The first 150 words of the full text of this article appear below.

1,25-Dihydroxy vitamin D (vitamin D) is a hormone with a number of pharmacological and physiological effects, first demonstrated as the effect to cure osteomalacia and later as a hormone with effects related to mineral homeostasis, cell differentiation, immunology, vascular calcification and ageing [3–5]. The hormone, 1,25-dihydroxy vitamin D, is formed from cholecalciferol, that is 25-hydroxylated in the liver and 1-{alpha}-hydroxylated in the kidney. In addition 1-{alpha}-hydroxylase activity has been demonstrated in a number of cells outside the kidney. The activity of the extrarenal 1-{alpha}-hydroxylase is, however, not enough to keep physiological plasma levels of 1,25-dihydroxy vitamin D, and the renal 1-{alpha}-hydroxylase activity is therefore of utmost importance for maintaining a normal physiological homeostasis.

In patients with chronic uraemia, reduced kidney mass and low kidney function, the renal 1-{alpha}-hydroxylase activity is clearly reduced, as demonstrated by the very low levels of plasma 1,25-dihydroxy vitamin . . . [Full Text of this Article]



   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
T. B. Drueke and E. Ritz
Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Olgaard and E. Lewin
Reply to Dr S.C. Palmer and co-workers
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2709 - 2710.
[Full Text] [PDF]